Evidence map›Paper›PMID 37990424›Full record

ArticleCurrent cancer drug targets2024

ZIP14 Affects the Proliferation, Apoptosis, and Migration of Cervical Cancer Cells by Regulating the P38 MAPK Pathway.

Lixia Jiang, Ting Xie, Yu Xia, Feng Li, Tianyu Zhong, Mi Lai

Abstract read
PubMed Publisher
In one paragraph

Article in Current cancer drug targets, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Reduction in the hepatocellular carcinoma antioncogeneWorld journal of gastrointestinal surgery · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Lixia JiangDepartment of Laboratory Medicine, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, 341000, China.
Ting XieGannan Medical University, Ganzhou, Jiangxi, 341000, China.
Yu XiaDepartment of Laboratory Medicine, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, 341000, China.
Feng LiDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, 341000, China.
Tianyu ZhongDepartment of Laboratory Medicine, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, 341000, China.
Mi LaiDepartment of Laboratory Medicine, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, 341000, China.
First Affiliated Hospital of Gannan Medical University · CNGannan Medical University · CN

Funding

Gannan Medical University Project YB201823
6 · The paper itself

Abstract

backgroundCervical cancer (CC) remains a major public health concern and is a leading cause of female mortality worldwide. Understanding the molecular basis of its pathogenesis is essential for the development of novel therapeutic strategies. In this study, we aimed to dissect the role of a specific molecule, ZIP14, in the initiation and progression of CC.

methodsWe used Gene Expression Omnibus for target gene identification, while KEGG was used to delineate CC-related pathways. Proliferation, migration, and apoptosis levels in CC cells were assessed using CCK8, Transwell, and flow cytometry, respectively. The effect of the target genes on the

resultsZIP14 (SLC39A14) was found to be underexpressed in CC samples. Our KEGG pathway analysis revealed the potential involvement of the P38 mitogen-activated protein kinase (MAPK) pathway in CC pathogenesis. Overexpression of ZIP14 in HeLa and Caski cells increased p38 phosphorylation, inhibited cell growth and migration, and enhanced apoptosis. Conversely, ZIP14 knockdown produced the opposite effects. Importantly, the bioeffects induced by ZIP14 overexpression could be counteracted by the p38 MAPK pathway inhibitor SB203580.

conclusionOur study is the first to elucidate the pivotal role of ZIP14 in the pathogenesis of CC, revealing its inhibitory effects through the activation of the p38 MAPK signaling pathway. The discovery not only provides a deeper understanding of CC's molecular underpinnings, but also highlights ZIP14 as a promising therapeutic target. As ZIP14 holds significant potential for therapeutic interventions, our findings lay a robust foundation for further studies and pave the way for the exploration of novel treatment modalities for cervical cancer.

Indexed as

ApoptosisCell MovementCell Proliferationp38 Mitogen-Activated Protein KinasesUterine Cervical NeoplasmsAnimalsCation Transport ProteinsFemaleGene Expression Regulation, NeoplasticHeLa CellsHumansMAP Kinase Signaling SystemMiceMice, Inbred BALB CMice, NudeXenograft Model Antitumor AssaysCation Transport Proteinsp38 Mitogen-Activated Protein KinasesapoptosisCervical cancerGEOlevels.P38 MAPKpathogenesisZIP14

Identifiers

PMID37990424
OpenAlexW4388911502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.